Definium’s late-stage pipeline includes four Phase 3 trials—two each for GAD and MDD—anchored by its lead candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD.

China opened 2026 by signaling that its most advanced military capabilities are no longer reserved for occasional ...

EDM Resources Inc. (TSXV: EDM) (FSE: P3Z) ("EDM" or the "Company") is pleased to provide a summary of its key accomplishments during 2025 ...

Establishment Labs Holdings Inc. , a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced ...

ISS cites flexibility for NuVista Shareholders to realize certain cash value or continued participation in endorsing the ArrangementYour vote is important – Vote well in advance of the proxy voting ...